Contact this trialFirst, we need to learn more about you.
ALK Inhibitor
Lorlatinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 2
Boston, Massachusetts
This trial will test the safety and effectiveness of the lorlatinib in treating patients with ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC).
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.